The Valley Desk

NCT02707601 · Interventional trial

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Overall registry status Completed

Phase 3

Conditions HCV Infection, HIV-1 Infection

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov